Hermetica Superfood Encyclopedia
The Short Answer
Myrrh resin contains triterpenoids (guggulsterones, myrrhanol A), sesquiterpenes (furanoeudesma-1,3-diene, curzerene), and phenolics that suppress inflammatory signaling through NF-κB inhibition, COX-1/COX-2 blockade, and iNOS suppression at micromolar concentrations. In vitro wound-healing studies demonstrate 98.4% fibroblast wound closure at a sub-cytotoxic dose of 10 µg/mL, while E-guggulsterone achieves 83% COX-2 inhibition at 100 ppm, though these findings await confirmation in human clinical trials.
CategoryHerb
GroupAfrican
Evidence LevelPreliminary
Primary Keywordmyrrh benefits
Myrrh — botanical close-up
Health Benefits
**Wound Healing**: Myrrh resin extract promotes 98
4% wound closure in fibroblast scratch assays at 10 µg/mL, attributed to terpenoids and flavonoids that stimulate cell migration and proliferation while simultaneously suppressing infection at the wound site.
**Anti-Inflammatory Activity**
E- and Z-guggulsterones inhibit NF-κB transcriptional activation and suppress nitric oxide production with IC₅₀ values of 1.1 µM and 3.3 µM respectively, reducing the upstream cytokine cascade driving chronic and acute inflammation.
**Antimicrobial Protection**
Terpenoids, phenolics, and flavonoids within the resin disrupt microbial membrane integrity and metabolic pathways, demonstrated through minimum inhibitory concentration assays across a broad spectrum of Gram-positive and Gram-negative bacteria relevant to wound infections.
**Antioxidant Defense**
Diterpenes, sesquiterpenoids, and sterols donate electrons to neutralize free radicals; the ethyl acetate fraction yields an IC₅₀ of 0.92 mg/mL in DPPH assays, and furano-sesquiterpenoid fractions show IC₅₀ values between 1.08–4.29 mg/mL.
**Analgesic Effects**
Sesquiterpene-standardized liquid extract (MyrLiq) has been evaluated for pain modulation, with furanoeudesma-1,3-diene and related furanodiene compounds (totaling 40.86 ± 0.78 g/kg in MyrLiq) implicated in central and peripheral analgesic pathways.
**Cholinesterase Inhibition**
Methanol extracts of bark, leaves, and resin inhibit acetylcholinesterase (AChE) by 17–29.33%, and molecular docking identifies abietic acid as a key ligand with a binding affinity of −10.5 kcal/mol, suggesting potential neuroprotective relevance.
**COX Enzyme Suppression**
E-guggulsterone inhibits COX-1 by 79% and COX-2 by 83% at 100 ppm, while cembrene achieves 67% COX-1 and 54% COX-2 inhibition at the same concentration, providing a dual cyclooxygenase blockade relevant to pain and inflammatory conditions.
Origin & History
Natural habitat
Commiphora myrrha is a thorny, small tree native to the arid regions of the Horn of Africa—particularly Somalia, Ethiopia, and Eritrea—and extending into the Arabian Peninsula, thriving in rocky, well-drained soils at low to mid elevations. The oleogum resin is obtained by making incisions in the bark, from which a pale yellow liquid exudes and hardens into reddish-brown irregular lumps upon contact with air. Traditionally, Somali and Ethiopian communities have harvested wild stands rather than cultivating the species formally, though sustainable harvesting practices are increasingly studied given overexploitation pressures.
“Myrrh holds one of the longest documented histories of any medicinal substance, appearing in ancient Egyptian papyri (circa 1550 BCE, Ebers Papyrus) as a wound treatment, embalming agent, and incense component, and referenced in the Hebrew Bible, Greek pharmacopoeia (Dioscorides' De Materia Medica), and Islamic tibb (prophetic medicine) traditions. In Somali and Ethiopian ethnomedicine, the resin is a primary wound-care material applied topically to lacerations, burns, and infected skin, and is consumed orally for oral ulcers, gastrointestinal complaints, and as a postpartum anti-inflammatory treatment. Ayurvedic tradition incorporates a closely related species (Commiphora wightii, guggul) for joint disease and lipid management, reflecting a shared recognition of triterpenoid bioactivity across South Asian and East African medical systems. Myrrh was one of the three gifts presented by the Magi in Christian tradition and was traded along ancient Incense Routes, making it among the most economically significant botanicals in pre-modern history.”Traditional Medicine
Scientific Research
The evidence base for Commiphora myrrha consists predominantly of in vitro cell culture studies and limited animal pharmacology experiments, with no large-scale randomized controlled trials (RCTs) published as of current data. Key in vitro findings include fibroblast wound-closure assays (98.4% closure at 10 µg/mL), DPPH radical scavenging experiments, AChE inhibition assays, and COX-1/COX-2 enzymatic inhibition studies using isolated compounds at defined concentrations. One pilot-scale human study investigated MyrLiq (a standardized sesquiterpene extract) for analgesic properties, but full sample sizes, power calculations, and p-values are not robustly reported in the accessible literature. Systematic reviews and meta-analyses are absent for this specific species, and the evidence base—while mechanistically compelling—must be considered preliminary pending well-designed human trials.
Preparation & Dosage
Traditional preparation
**Traditional Resin Emulsion**
1–5 g resin per 200 mL water) for oral intake or topical wound application; no standardized clinical dose established
The raw gum-resin is crushed and emulsified in warm water (approximately .
**Ethanolic Extract (Oral/Topical)**
92 mg/mL DPPH); no validated human oral dose
Prepared by macerating resin in 70–96% ethanol; ethyl acetate fractionation yields the highest antioxidant potency (IC₅₀ 0..
**Essential Oil (Topical/Aromatherapy)**
Steam-distilled from resin; contains 2–8% volatile fraction rich in sesquiterpenes; typically diluted to 1–3% in carrier oil for topical wound application.
**MyrLiq Standardized Liquid Extract**
86 g/kg); evaluated in pilot analgesic studies; specific dosage protocols not publicly defined
Commercial product standardized to total furanodiene sesquiterpenes (~40..
**Powdered Resin (Capsules)**
300–500 mg capsules in traditional markets; no RCT-validated dose; Ayurvedic tradition references 1–3 g/day of crude resin for short-term use
Commonly sold in .
**Standardization Note**
Optimal extracts should specify sesquiterpene content (curzerene, furanoeudesma-1,3-diene) and triterpenoid content (guggulsterones); solvent polarity significantly influences active compound yield.
Nutritional Profile
Commiphora myrrha gum-resin is not a dietary food source and contributes negligible macronutrients. Its bioactive profile is characterized by: resin fraction (23–40%, containing triterpenoids such as myrrhanol A, myrrhanone A, guggulsterones E and Z, mukulol, and commiphorinic acid), gum fraction (40–60%, composed of polysaccharides including arabinose, galactose, and glucuronic acid polymers providing the emulsifying matrix), and volatile oil fraction (2–8%, dominated by sesquiterpenes: furanoeudesma-1,3-diene 18.84 ± 0.02 g/kg, total furanodiene 40.86 ± 0.78 g/kg, curzerene 12.31 ± 0.05 g/kg, lindestrene 6.23 ± 0.01 g/kg, β-elemene 8.4%, δ-elemene 0.5%). Minor constituents include β-sitosterol, flavonoids, lignans (primarily in stem bark), and commiferin. Bioavailability is significantly influenced by extraction solvent polarity; ethyl acetate fractions yield superior antioxidant activity over aqueous or hexane fractions, suggesting lipophilic partitioning enhances absorption of key terpenoids.
How It Works
Mechanism of Action
Guggulsterones (E- and Z-isomers) suppress the NF-κB signaling pathway by blocking IκB kinase activation, thereby reducing transcription of pro-inflammatory cytokines (TNF-α, IL-1β, IL-6) and inducible nitric oxide synthase (iNOS); E-guggulsterone achieves NO suppression with an IC₅₀ of 1.1 µM in macrophage models. Triterpenoids myrrhanol A and mukulol further attenuate iNOS protein induction, reducing nitric oxide-mediated oxidative tissue damage at the cellular level. Sesquiterpene furanodienones—particularly furanoeudesma-1,3-diene and curzerene—interact with opioid receptors and inhibit cyclooxygenase enzymes (COX-1/COX-2), providing both peripheral and potentially central analgesic modulation. Phenolic and flavonoid constituents contribute antioxidant activity through direct radical scavenging and may modulate Nrf2-mediated antioxidant response element (ARE) gene expression, though this last pathway requires dedicated mechanistic validation in myrrh-specific studies.
Clinical Evidence
No large-scale Phase II or Phase III RCTs examining Commiphora myrrha for wound healing, analgesia, or anti-inflammatory endpoints have been published. The MyrLiq pilot analgesic study represents the most clinically proximate human data, evaluating a sesquiterpene-standardized extract, but lacks the rigor (blinding, power, control arms) necessary for clinical recommendation. Preclinical outcomes are consistent and mechanistically plausible—particularly the wound-healing and anti-inflammatory data—but effect size translation to human physiology is unconfirmed. Clinicians should regard current evidence as hypothesis-generating rather than practice-changing, supporting the need for funded Phase I/II trials in wound care settings relevant to Somali and Ethiopian traditional use contexts.
Safety & Interactions
At low sub-toxic concentrations (≤10 µg/mL in cell culture), myrrh extract demonstrates a hormetic profile—promoting fibroblast proliferation and wound closure—while crude ethanolic extracts exhibit cytotoxicity with an IC₅₀ of 24.53 µg/mL on fibroblasts and 97% cell inhibition at 1000 µg/mL, suggesting a narrow therapeutic window for unfractionated preparations. No formal drug interaction studies have been published for Commiphora myrrha specifically; however, the guggulsterone content warrants caution with anticoagulant/antiplatelet drugs (warfarin, aspirin), thyroid hormone medications (guggulsterones modulate thyroid receptor signaling), and immunosuppressants given NF-κB pathway modulation. Myrrh is contraindicated in pregnancy based on historical documentation of uterotonic activity and absence of safety data; lactating individuals should also avoid therapeutic doses pending evidence. The maximum safe oral dose in humans has not been formally established through toxicological studies, and use of high-dose crude resin extracts beyond short-term traditional applications (typically 1–2 weeks) is not supported by current evidence.
Synergy Stack
Hermetica Formulation Heuristic
Also Known As
Commiphora myrrhaCommiphora molmolAfrican myrrhSomali myrrhherabol myrrhmirra
Frequently Asked Questions
What is myrrh resin used for in traditional Somali and Ethiopian medicine?
In Somali and Ethiopian traditional practice, myrrh resin is primarily applied topically to wounds, lacerations, and burns to prevent infection and accelerate healing, and consumed orally for oral ulcers, postpartum recovery, and gastrointestinal discomfort. The resin is typically crushed and emulsified in warm water or applied directly as a paste. These uses align with in vitro data showing 98.4% fibroblast wound closure at 10 µg/mL and broad-spectrum antimicrobial activity attributed to terpenoid and flavonoid constituents.
What are the main active compounds in myrrh and how do they work?
The principal bioactive compounds in Commiphora myrrha are guggulsterones (E- and Z-isomers), sesquiterpenes (furanoeudesma-1,3-diene, curzerene, lindestrene), and triterpenoids (myrrhanol A, mukulol). E-guggulsterone suppresses NF-κB signaling and inhibits COX-2 by 83% at 100 ppm, while furanoeudesma-1,3-diene (18.84 g/kg in standardized extract) interacts with opioid receptors for analgesic effects. Together, these compounds provide anti-inflammatory, antimicrobial, antioxidant, and wound-healing actions through complementary molecular mechanisms.
Is there clinical trial evidence supporting myrrh supplementation?
Human clinical evidence for Commiphora myrrha remains very limited; no large-scale randomized controlled trials have been published. The most clinically relevant human data comes from a pilot study of MyrLiq, a sesquiterpene-standardized extract, evaluated for analgesic effects, though full statistical outcomes are not robustly reported in accessible literature. The current evidence base is predominantly in vitro and preclinical, meaning that while the mechanisms are compelling, myrrh cannot yet be clinically recommended for specific indications beyond traditional supportive use.
What are the side effects and safety concerns of taking myrrh?
At low doses consistent with traditional use (approximately 1–5 g crude resin short-term), myrrh is generally considered tolerable, but crude ethanolic extracts demonstrate cytotoxicity at higher concentrations (IC₅₀ 24.53 µg/mL on fibroblasts, 97% inhibition at 1000 µg/mL), indicating a narrow safety margin for unfractionated high-dose preparations. Myrrh is contraindicated during pregnancy due to historical reports of uterotonic effects and absence of safety data. Those taking anticoagulants, thyroid medications, or immunosuppressants should consult a healthcare provider before use, as guggulsterone content may interact with these drug classes.
How is myrrh extract standardized and what dose should I take?
Commercial standardized myrrh extracts such as MyrLiq specify sesquiterpene content, with total furanodiene fractions quantified at approximately 40.86 g/kg and curzerene at 12.31 g/kg as quality markers. No validated human clinical dose has been established through RCTs; traditional Ayurvedic references suggest 1–3 g/day of crude resin for short-term use (1–2 weeks), while wound-healing in vitro efficacy is observed at sub-toxic concentrations of 10 µg/mL. For topical wound applications, essential oil is typically diluted to 1–3% in a carrier oil, and resin emulsions are prepared at roughly 1–5 g per 200 mL water following traditional methods.
Does myrrh interact with blood thinners or anticoagulant medications?
Myrrh contains compounds that may have mild antiplatelet properties, so concurrent use with warfarin, aspirin, or other anticoagulants should be discussed with a healthcare provider to avoid additive effects. While traditional use alongside these medications is not well-documented in clinical literature, caution is warranted due to myrrh's potential effects on blood clotting pathways. Always inform your physician if you are taking myrrh supplements while on anticoagulant therapy.
Is myrrh safe to use during pregnancy and breastfeeding?
Myrrh is traditionally contraindicated in pregnancy due to its potential uterotonic properties and historical use as an emmenagogue, making it prudent to avoid supplementation during pregnancy. Limited safety data exists for myrrh use during breastfeeding, so nursing mothers should consult a healthcare provider before supplementing. Pregnant and breastfeeding women should use myrrh only under medical supervision if benefits are deemed necessary.
How does myrrh compare to frankincense for wound healing and inflammation?
Both myrrh and frankincense contain boswellic acids and terpenoids that support wound healing and reduce inflammation, but myrrh demonstrates superior wound closure rates (98.4% in fibroblast assays) and more potent bacterial inhibition at wound sites compared to frankincense. Frankincense is often preferred for joint inflammation and arthritis due to its specific effects on cartilage degradation, while myrrh excels in topical wound and oral mucosal applications. Combining both may offer complementary benefits, though individual response varies.
Explore the Full Encyclopedia
7,400+ ingredients researched, verified, and formulated for optimal synergy.
Browse IngredientsThese statements have not been evaluated by the Food and Drug Administration. This content is for informational purposes only and is not intended to diagnose, treat, cure, or prevent any disease.
hermetica-encyclopedia-canary-zzqv9k4w myrrh-commiphora-myrrha curated by Hermetica Superfoods at ingredients.hermeticasuperfoods.com and licensed CC BY-NC-SA 4.0 (non-commercial share-alike, attribution required)
